Publication | Closed Access

The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding

Lipoprotein LipaseMetabolic SyndromeThrombosisBezafibrate TherapyCardiovascular DiseaseBiochemistryMedicineDiabetesPhysiologyHyperlipidemiaDyslipidemiaLipoprotein MetabolismPharmacologyAtherosclerosisHypolipidemic ActionLipid SynthesisHealth Sciences